نبذة مختصرة : The article is a review of literature on the prevalence of post-stroke depression, its causes, pathogenesis, clinical patterns and diagnosis of the disease. Depression has a negative effect on the process of post-stroke rehabilitation, quality of life, physical health of patients and increases the risk of death in patients after stroke. The advantages of SSRI antidepressants in the treatment of post-stroke depression are demonstrated; there are results of randomized clinical trials (RCTs) of high safety, tolerability and efficacy of sertraline. Options for prevention of post-stroke depression are discussed. ; В статье представлены данные литературы о распространенности постинсультной депрессии, причинах возникновения, патогенезе, особенностях клинической картины и диагностики заболевания. Показано негативное влияние на процесс реабилитации после инсульта, качество жизни, соматическое здоровье больных, повышение риска смертности при возникновении депрессии у пациента, перенесшего инсульт. Обоснованы преимущества антидепрессантов из группы СИОЗС в лечении постинсультной депрессии, приведены результаты рандомизированных клинических исследований (РКИ) о высокой безопасности, хорошей переносимости и эффективности сертралина. Обсуждаются возможности профилактики постинсультной депрессии.
Relation: https://www.med-sovet.pro/jour/article/view/1660/1620; Каннер А.М. Депрессия при неврологических заболеваниях. М.: Литтерра, 2007, 159 с.; Hackett ML, Yapa C, Parag V et al. Frequency depression after stroke: a systematical review of observational studies. Stroke, 2005, 36: 1330-40.; Скворцова В.И., Губский Л.В., Стаховская Л.В. и др. Ишемический инсульт. В кн.: Неврология, национальное руководство. Под ред. Е.И. Гусева, А.И. Коновалова, В.И. Скворцовой. М.: ГЭОТАР-Медиа, 2009: 593-615.; Starkstein SE, Robinson RG, Berther ML et al. Depressive disorders following posterior circulation as compared with middle cerebral artery infarcts. Brain, 1988, 11: 375-87.; Berg A, Palomaki H. Poststroke depression. An 18-monthfollow-up. Stroke, 2003, 34: 138-43.; Gaete JM, Bogousslavsky J. Post-stroke depression. Exp Rev Neurother, 2008, 8: 75-92.; Lökk J, Delbar А. Management of depression in elderly stroke patients. Neuropsychiatr, Dis Treat 2010, 6: 539-49.; Вознесенская Т.Г. Депрессия при цереброваскулярных заболеваниях. Неврол. нейропсихиатр и психосом., 2009, 2: 9-13.; Ramasubbu R, Tobias R, Buchan AM et al. Serotonin transporter gen promoter region polymorphism associated with post-stroke major depression. J Neuropsychiatry Clin Neurosci, 2006, 18: 96-9.; Landreville P, Desrosiers J, Vincent C, Verreault R, Boudreault V. BRAD Group. The role of activity restriction in poststroke depressive symptoms. Rehabil Psychol, 2009, Aug, 54(3): 315-322.; Mayberg HS, Robinson RG, Wong DF. PET imaging of cortical S2 receptors after stroke: later-alized changes and relationship to depression. Am J Psychiatry, 1988, 145: 937-943.; Pascoe MC, Crewther SG, Carey LM, Crewther DP. Inflammation and depression: why post-stroke depression may be the norm and not the exception. International Journal of Stroke, 2011, 6(2): 128-135.; Wang Q, Tang XN, Yenari MA. The inflammatory responce in stroke. J Neuroimmunology, 2007, 184(1-2): 53-68.; Sorbello D, Dewey HM, Churilov L, Thrift AG, Collier JM, Donnan G, Bernhardt J. Very early mobilisation and complications in the first 3 months after stroke: further results from phase II of A Very Early Rehabilitation Trial (AVERT). Cerebrovasc Dis, 2009, 28(4): 378-383.; Cipriani A, Furukawa TA, Salanti G, Geddes JR, Julian PT, Higgin JPT, Churchil R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet, 2009, 373: 746-758.; Sheikh JI, Cassidy EL, Doraiswamy PM et al. Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc, 2004, 52: 86-92.; Thorlund K, Druyts E, Wu P et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc, 2015, 63: 1002-1009.; Xiong GL, Fiuzat M, Kuchibhatla M et al. Health status and depression remission in patients with chronic heart failure: patient-reported out comes from the SADHART-CHF trial. Circ Heart Fail, 2012, 5: 688-692.; Serebruany VL, Glassman AH, Malinin AI et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy. Circul, 2003, 108: 939-944.; Murray V, von Arbin M, Bartfai A, Berggren AL et al Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatr, 2005 Jun, 66(6): 708-16.; Костенко Е.В., Энеева М.Е., Бобырева С.Н. Антидепрессанты в комплексной терапии депрессивных расстройств и нарушений сна в постинсультном периоде. Медицинский алфавит, 2015, 2(19): 19-24.; Palomäki H, Kaste M, Berg A, et al. Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mainserin with 6 month follow up after therapy. J Neurol Neurosurg Psychiatry, 1999, 66(4): 490-494.; Rasmussen A, Lunde M, Poulsen DL et al. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics, 2003, 44(3): 216-221.; Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: results from a rand-omized placebo-controlled trial. J Clin Psychiatry, 2006, 67(7): 1104-1109.; Robinson RG, Jorge RE, Moser DJ et al. Escitalo-pram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA, 2008, 299(20): 2391-2400.; https://www.med-sovet.pro/jour/article/view/1660
Processing Request
No Comments.